Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
Infect Genet Evol ; 85: 104503, 2020 11.
Article in English | MEDLINE | ID: mdl-32805431

ABSTRACT

Intermittent preventive treatment in pregnancy with sulphadoxine-pyrimethamine (IPTp-SP) is one of the main strategies for protecting pregnant women, fetus, and their new-born against adverse effects of P. falciparum infection. The development of the drug resistance linked to mutations in P. falciparum dihydrofolate reductase gene (pfdhfr) and P. falciparum dihydropteroate synthase gene (pfdhps), is currently threatening the IPTp-SP approach. This study determined the prevalence of pfdhfr and pfdhps mutations in isolates obtained from pregnant women with asymptomatic P. falciparum infection in Nigerian. Additionally, P. falciparum genetic diversity and multiplicity of infection (MOI) was assessed by genotyping the P. falciparum merozoite surface Protein 1 and 2 (pfmsp-1 and pfmsp-2) genes. The pfdhfr and pfdhps were genotyped by direct sequencing, and the pfmsp-1 and pfmsp-2 fragment analysis by polymerase chain reaction was used to determine P. falciparum genetic diversity. Of the 406 pregnant women recruited, 123 had P. falciparum infection by PCR, and of these, 52 were successfully genotyped for pfdhfr and 42 for pfdhps genes. The pfdhfr triple-mutant parasites (N51I, C59R, and S108N) or the IRN haplotype were predominant (98%), whereas pfdhfr mutations C50R and I164L did not occur. For pfdhps gene, the prevalence of A437G, A581G, A436A, and A613S mutations were 98, 71, 55, and 36%, respectively. Nineteen (44%) isolates with quintuple mutations (CIRNI- SGKGA) had the highest combined pfdhfr-pfdhps haplotype. Isolates with sextuple mutants; CIRNI- AGKAS and CIRNI- AGKGA had a prevalence of 29 and 14%, respectively. High genetic diversity (7 pfmsp-1 alleles and 10 pfmsp-2 alleles) and monoclonal infection rate (76%) was observed. This study demonstrated a continuous high prevalence of pfdhfr mutation and an increase in pfdhps mutations associated with SP-resistance in southwest Nigeria. Continuous surveillance of IPTp-SP effectiveness and consideration of alternative IPTp strategies is recommended.


Subject(s)
Antimalarials/therapeutic use , Drug Resistance/genetics , Malaria, Falciparum/drug therapy , Plasmodium falciparum/drug effects , Plasmodium falciparum/genetics , Pyrimethamine/therapeutic use , Sulfadoxine/therapeutic use , Adult , Dihydropteroate Synthase/genetics , Drug Combinations , Female , Genotype , Humans , Mutation , Nigeria , Polymorphism, Genetic , Pregnancy , Pregnant Women , Sequence Analysis, DNA , Tetrahydrofolate Dehydrogenase/genetics
2.
Malar J ; 19(1): 178, 2020 May 08.
Article in English | MEDLINE | ID: mdl-32384930

ABSTRACT

BACKGROUND: Malaria in pregnancy is associated with considerable morbidity and mortality. Regular surveillance of artemisinin-based combination therapy tolerance, or molecular makers of resistance, is vital for effective malaria treatment, control and eradication programmes. Plasmodium falciparum multiple drug resistance-1 gene (Pfmdr1) N86Y mutation is associated with reduced susceptibility to lumefantrine. This study assessed the prevalence of Pfmdr1 N86Y in Brazzaville, Republic of Congo. METHODS: A total 1001 of P. falciparum-infected blood samples obtained from asymptomatic malaria pregnant women having a normal child delivery at the Madibou Integrated Health Centre were analysed. Pfmdr1 N86Y genotyping was conducted using PCR-restriction fragment length polymorphism. RESULTS: The wild type Pfmdr1 N86 allele was predominant (> 68%) in this study, whereas a few isolates carrying the either the mutant allele (Pfmdr1 86Y) alone or both alleles (mixed genotype). The dominance of the wildtype allele (pfmdr1 N86) indicates the plausible decline P. falciparum susceptibility to lumefantrine. CONCLUSION: This study gives an update on the prevalence of Pfmdr1 N86Y alleles in Brazzaville, Republic of Congo. It also raises concern on the imminent emergence of resistance against artemether-lumefantrine in this setting. This study underscores the importance to regular artemether-lumefantrine efficacy monitoring to inform the malaria control programme of the Republic of Congo.


Subject(s)
Antimalarials/pharmacology , Drug Resistance/genetics , Lumefantrine/pharmacology , Multidrug Resistance-Associated Proteins/genetics , Plasmodium falciparum/genetics , Adolescent , Adult , Congo , Female , Humans , Multidrug Resistance-Associated Proteins/metabolism , Mutation , Plasmodium falciparum/drug effects , Polymorphism, Restriction Fragment Length , Pregnancy , Young Adult
4.
Acta Trop ; 196: 121-125, 2019 Aug.
Article in English | MEDLINE | ID: mdl-31103699

ABSTRACT

Prompt diagnosis and appropriate treatment of malaria remain the hallmark for reducing malaria-related mortality in high transmission areas. Plasmodium falciparum histidine-rich protein2 (PfHRP2) based rapid diagnostic tests (RDT) play a vital role in prompt and accurate malaria diagnosis. However, pfhrp2 gene deletion threatens the RDT test sensitivity. This study reports the presence of pfhrp2 and pfhrp3 genes deletion among parasite isolates in Nigeria. Febrile children were screened using histidine-rich protein (HRP2) specific RDT (SD-Bioline RDT) and microscopy for P. falciparum infections. All RDT negative samples were re-evaluated by polymerase chain reaction (PCR). The presence of parasite in RDT false negative cases and randomly selected RDT positive cases were validated using PCRs targeting glutamate-rich protein (glurp) and merozoite surface proteins (msp-1 and msp-2). Thereafter, exon 2 of pfhrp2 and pfhrp3 were amplified, and Sanger sequenced. A total of 511 febrile children were enrolled out of which 309 (61%) were positive by RDT. The presence of pfhrp2 and pfhrp3 genes were analyzed in 66 PCR positive samples comprising of 31 RDT false negative and 35 RDT true positive randomly selected samples. The pfhrp2 and pfhrp3 genes failed to amplify in 17% (11/66) and 6% (4/66) samples, respectively. Seven of the eleven samples had only pfhrp2 deletion while four had both pfhrp2 and pfhrp3 deletions. The absence of the pfhrp2 gene may be responsible for the seven RDT false negative cases observed. Three RDT positive cases lacked pfhrp2 whereas pfhrp3 was absent in only four RDT false negative cases. The pfhrp2 and pfhrp3 amino acid repeat sequences were highly diverse. The P. falciparum isolates lacking pfhrp2 and pfhrp3 genes may be circulating and contributing to RDT false negativity in Nigeria. More studies in larger population and seasonally defined cases will be needed to determine the extent of pfhrp2/3 genes deletion in different geographical areas of Nigeria.


Subject(s)
Antigens, Protozoan/genetics , Diagnostic Tests, Routine/methods , Malaria, Falciparum/parasitology , Plasmodium falciparum/genetics , Protozoan Proteins/genetics , Child, Preschool , Gene Deletion , Humans , Malaria, Falciparum/epidemiology , Nigeria/epidemiology , Polymerase Chain Reaction
5.
Int J Infect Dis ; 85: 49-53, 2019 Aug.
Article in English | MEDLINE | ID: mdl-31078747

ABSTRACT

BACKGROUND: Cytochrome P450 (CYP) enzymes are essential in the metabolism of most drugs used today. Single nucleotide polymorphism(s) occurring in CYP genes can adversely affect drug pharmacokinetics, efficacy, and safety. Individuals carrying the CYP2C8*2 c.805A > T (CYP2C8*2; rs11572103) allele have impaired amodiaquine metabolism, increased risk of amodiaquine-related adverse events, and may promote the selection of drug-resistant parasite strains. This study investigated the distribution of the CYP2C8*2 allele in Brazzaville, Republic of Congo, where artesunate + amodiaquine is used as the second-line treatment for uncomplicated Plasmodium falciparum malaria. METHODS: A total of 285 febrile children visiting the Marien Ngouabi paediatric hospital were genotyped for CYP2C8*2 using PCR-restriction fragment length polymorphism (PCR-RFLP). The allele frequencies and genotype distribution were determined. RESULTS: The CYP2C8*2 allele was successfully genotyped in 75% (213/285) of the study participants. The CYP2C8*2A allele had a frequency of 63%, whereas the CYP2C8*2T allele had a frequency of 37%. Genotypes CYP2C8*2AA (rapid metabolizer), CYP2C8*2AT (intermediate metabolizer), and CYP2C8*2TT (poor metabolizer) were observed in 44%, 38%, and 18% of the investigated participants, respectively. CONCLUSIONS: This study gives the first description of CYP2C8*2 allele distribution in the Republic of Congo and highlights the potential risk of amodiaquine-related adverse events. Information from this study will be beneficial during pharmacovigilance investigations.


Subject(s)
Amodiaquine/therapeutic use , Antimalarials/therapeutic use , Cytochrome P-450 CYP2C8/genetics , Malaria, Falciparum/drug therapy , Malaria, Falciparum/genetics , Alleles , Artemisinins/therapeutic use , Child , Child, Preschool , Congo , Drug Combinations , Female , Gene Frequency , Genotype , Humans , Infant , Malaria, Falciparum/enzymology , Male , Polymorphism, Restriction Fragment Length , Polymorphism, Single Nucleotide
6.
Int J Infect Dis ; 82: 111-116, 2019 May.
Article in English | MEDLINE | ID: mdl-30818046

ABSTRACT

BACKGROUND: The cytochrome P450 CYP2B6*6 (CYP2B6 c.516G>T; rs3745274) is one of the genetic factors that alters the drug metabolism in antimalarial, antiretroviral and TB first-line drugs. In Central African populations, the distribution of the CYP2B6*6 variant is poorly documented. This study investigated the distribution of CYP2B6 c.516G>T variant among Congolese individuals. METHODS: A total of 418 patients with HIV-1 mono-infection, HIV-1 and Tuberculosis coinfection and symptomatic P. falciparum malaria were genotyped for the CYP2B6 c.516G>T SNP using Restriction Fragment Length Polymorphism (RFLP). The allele frequencies and genotype distributions were determined. RESULTS: The CYP2B6 c.516G>T was successfully analysed in 69% (288/418) of the study participants. Among the investigated individuals, the distribution of the major allele CYP2B6*G was 45% and the minor CYP2B6*T allele was 55%. Significant differences in genotype distribution were also observed among the studied individuals. The CYP2B6*GG (rapid metabolizer) genotype was observed in 17% (49/288) followed by CYP2B6*GT (intermediate metabolizer) 55% (159/288) and CYP2B6*TT (poor metabolizers) 28% (80/288). CONCLUSION: This study contributes to increasing understanding on population pharmacogenetics and may help policy makers regulate treatment guidelines in the Congolese population with a high burden of HIV, Malaria and TB.


Subject(s)
Cytochrome P-450 CYP2B6/genetics , Genetic Variation , HIV Infections/drug therapy , Malaria, Falciparum/drug therapy , Tuberculosis/drug therapy , Adolescent , Adult , Anti-Retroviral Agents/pharmacokinetics , Antimalarials/pharmacokinetics , Antitubercular Agents/pharmacology , Child , Child, Preschool , Congo , Female , Gene Frequency , Genetics, Population , Genotype , Humans , Infant , Male , Middle Aged , Young Adult
7.
Malar J ; 18(1): 57, 2019 Feb 28.
Article in English | MEDLINE | ID: mdl-30819192

ABSTRACT

BACKGROUND: Malaria transmission-blocking anti-malarial drugs, such as primaquine, offers an effective strategy for reducing the incidence of falciparum malaria. However, this drug induces haemolytic anaemia among glucose-6-phosphate dehydrogenase (G6PD) deficient individuals. The distribution of G6PD deficiency in Brazzaville, Republic of Congo and the association of G6PD deficiency with haemoglobin levels and blood cell counts were investigated. METHODS: A total of 212 febrile children were recruited for this study. Plasmodium falciparum diagnosis was conducted by microscopy and nested PCR. Sanger sequencing was used to assess G6PD deficiency by detecting 202G>A (rs1050828) and 376A>G (rs1050829) single nucleotide polymorphisms. RESULTS: Two hundred and twelve children were successfully genotyped for G6PD variants. Overall, 13% (27/212) of the children were G6PD deficient and 25% (25/100) females were heterozygous (11 BA- and 14 A+A-). The remaining 160 children had a normal G6PD genotype. The mean red blood and mean platelet counts were significantly lower in hemizygous male (G6PD A-) participants than in normal male (G6PD A+ or B) participants (p < 0.05). CONCLUSION: This study gives an update on G6PD deficiency among Congolese children. Understanding the distribution of G6PD deficiency in other geographical regions is recommended before primaquine is adopted in the malaria control programme.


Subject(s)
Glucosephosphate Dehydrogenase Deficiency/epidemiology , Child , Child, Preschool , Democratic Republic of the Congo/epidemiology , Erythrocyte Count , Female , Genotyping Techniques , Glucosephosphate Dehydrogenase Deficiency/complications , Glucosephosphate Dehydrogenase Deficiency/pathology , Humans , Incidence , Infant , Malaria, Falciparum/complications , Malaria, Falciparum/diagnosis , Male , Microscopy , Parasitemia/complications , Parasitemia/diagnosis , Platelet Count , Polymerase Chain Reaction , Polymorphism, Single Nucleotide , Sequence Analysis, DNA
8.
Trop Med Int Health ; 24(5): 647-656, 2019 05.
Article in English | MEDLINE | ID: mdl-30816614

ABSTRACT

Kenya has, in the last decade, made tremendous progress in the fight against malaria. Nevertheless, continued surveillance of the genetic diversity and population structure of Plasmodium falciparum is required to refine malaria control and to adapt and improve elimination strategies. Twelve neutral microsatellite loci were genotyped in 201 P. falciparum isolates obtained from the Kenyan-Ugandan border (Busia) and from two inland malaria-endemic sites situated in western (Nyando) and coastal (Msambweni) Kenya. Analyses were done to assess the genetic diversity (allelic richness and expected heterozygosity, [He ]), multilocus linkage disequilibrium ( ISA ) and population structure. A similarly high degree of genetic diversity was observed among the three parasite populations surveyed (mean He  = 0.76; P > 0.05). Except in Msambweni, random association of microsatellite loci was observed, indicating high parasite out-breeding. Low to moderate genetic structure (FST  = 0.022-0.076; P < 0.0001) was observed with only 5% variance in allele frequencies observed among the populations. This study shows that the genetic diversity of P. falciparum populations at the Kenyan-Ugandan border is comparable to the parasite populations from inland Kenya. In addition, high genetic diversity, panmixia and weak population structure in this study highlight the fitness of Kenyan P. falciparum populations to successfully withstand malaria control interventions.


Le Kenya a réalisé d'énormes progrès au cours de la dernière décennie dans la lutte contre le paludisme. Néanmoins, une surveillance continue de la diversité génétique et de la structure de la population de P. falciparum est nécessaire pour affiner la lutte contre le paludisme et pour adapter et améliorer les stratégies d'élimination. Douze loci microsatellites neutres ont été génotypés chez 201 isolats de P. falciparum provenant de la frontière entre le Kenya et l'Ouganda (Busia) et de deux sites d'endémie palustre situés dans l'ouest (Nyando) et sur la côte (Msambweni), au Kenya. Des analyses ont été effectuées pour évaluer la diversité génétique (richesse allélique et hétérozygotie attendue, ([He]), déséquilibre de parenté des multiple loci ( ISA ) et structure de la population. Un degré hautement similaire de diversité génétique a été observé parmi les trois populations de parasites étudiées (He = 0,76; P > 0,05). A l'exception de Msambweni, une association aléatoire entre les microsatellites a été observée, indiquant une forte reproduction des parasites. Une structure génétique faible à modérée (FST  = 0,022-0,076; P < 0,0001) a été observée avec seulement 5% de variance dans la fréquence des allèles observée parmi les populations. Cette étude montre que la diversité génétique des populations de P. falciparum à la frontière entre le Kenya et l'Ouganda est comparable à celle des populations de parasites à l'intérieur du Kenya. De plus, la diversité génétique élevée, la panmixia et la structure démographique faible dans cette étude soulignent l'aptitude des populations de P. falciparum du Kenya à résister aux interventions de lutte contre le paludisme.


Subject(s)
Alleles , Gene Frequency , Genetic Variation , Genotype , Malaria, Falciparum/parasitology , Microsatellite Repeats , Plasmodium falciparum/genetics , Communicable Disease Control , Genetics, Population , Humans , Kenya , Linkage Disequilibrium , Uganda
9.
Sci Rep ; 9(1): 1709, 2019 02 08.
Article in English | MEDLINE | ID: mdl-30737461

ABSTRACT

Plasmodium falciparum histidine-rich proteins 2 (PfHRP2) based RDTs are advocated in falciparum malaria-endemic regions, particularly when quality microscopy is not available. However, diversity and any deletion in the pfhrp2 and pfhrp3 genes can affect the performance of PfHRP2-based RDTs. A total of 400 samples collected from uncomplicated malaria cases from Kenya were investigated for the amino acid repeat profiles in exon 2 of pfhrp2 and pfhrp3 genes. In addition, PfHRP2 levels were measured in 96 individuals with uncomplicated malaria. We observed a unique distribution pattern of amino acid repeats both in the PfHRP2 and PfHRP3. 228 PfHRP2 and 124 PfHRP3 different amino acid sequences were identified. Of this, 214 (94%) PfHRP2 and 81 (65%) PfHRP3 amino acid sequences occurred only once. Thirty-nine new PfHRP2 and 20 new PfHRP3 amino acid repeat types were identified. PfHRP2 levels were not correlated with parasitemia or the number of PfHRP2 repeat types. This study shows the variability of PfHRP2, PfHRP3 and PfHRP2 concentration among uncomplicated malaria cases. These findings will be useful to understand the performance of PfHRP2-based RDTs in Kenya.


Subject(s)
Antigens, Protozoan/genetics , Malaria, Falciparum/diagnosis , Plasmodium falciparum/metabolism , Protozoan Proteins/genetics , Amino Acid Sequence , Antigens, Protozoan/metabolism , Diagnostic Tests, Routine , Evolution, Molecular , Exons , Humans , Kenya , Plasmodium falciparum/genetics , Plasmodium falciparum/isolation & purification , Protozoan Proteins/metabolism
10.
Parasitol Int ; 67(6): 793-799, 2018 Dec.
Article in English | MEDLINE | ID: mdl-30138695

ABSTRACT

Rapid diagnostic tests (RDT) are valuable tools that support prudent and timely use of antimalarial drugs, particularly if reliable microscopy is not available. However, the performance and reliability of these tests vary between and within geographical regions. The present study evaluated the performance of routine malaria RDT in Kenyan febrile patients in Busia County, Kenya. A cross sectional study design was employed to recruit febrile patients attending health facilities between August and November 2016. A total of 192 febrile patients who were slide positive and negative were evaluated for their infection status by nested PCR and RDTs (PfHRP2/pLDH). In addition, P. falciparum diversity of the histidine-rich proteins 2 and 3, that influences the RDT test results were determined. All individuals were P. falciparum positive. Among the investigated 192 febrile patients, 76 (40%) were positive by microscopy, 101 (53%) by RDTs and 80 (42%) were PCR positive. The performance of the CareStart™ HRP2/pLDH (pf) RDTs was better than microscopy (Sensitivity 94%; Specificity 75%) and Nucleic acid testing (sensitivity 95%, specificity 77%) with high negative predictive values, indicating the suitability of the RDT in routine practice. Specific pfhrp2/pfhrp3 deletions shown to associate with RDT false negativity was not observed. However, high genetic diversity among pfhrp2 gene was observed. Eleven new PfHRP2 and nine PfHRP3 repeats were observed. False positivity by microscopy and under reporting of infections may thus be a barrier in malaria control and elimination programs. The HRP2/pLDH(Pf) based RDT yet demonstrate to be an effective tool for malaria surveillance program.


Subject(s)
Antigens, Protozoan/genetics , Diagnostic Tests, Routine/methods , Malaria, Falciparum/diagnosis , Microscopy/methods , Plasmodium falciparum/genetics , Polymerase Chain Reaction/methods , Protozoan Proteins/genetics , Cross-Sectional Studies , Genetic Variation , Kenya , L-Lactate Dehydrogenase/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...